Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × entinostat × Clear all
NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

National Cancer Institute (NCI)

Phase 3 Active not recruiting
608 enrolled 18 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡